Precision Biosciences (DTIL) Current Deferred Revenue (2018 - 2025)

Precision Biosciences (DTIL) has 8 years of Current Deferred Revenue data on file, last reported at $6.2 million in Q3 2025.

• Current Deferred Revenue for Q3 2025 came in at $6.2 million, up 3470.29% year-over-year; the trailing twelve-month figure through Sep 2025 was $6.2 million (up 3470.29% YoY), and the FY2024 annual result was $3.0 million, down 75.43% from the prior year.
• Current Deferred Revenue advanced to $6.2 million in Q3 2025 per DTIL's latest filing, from $6.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $53.1 million in Q1 2021 and troughed at $175000.0 in Q3 2024.
• A 5-year average of $20.5 million and a median of $19.7 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue slumped 99.0% in 2024, then jumped 3470.29% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $21.2 million in 2021, then surged by 117.44% to $46.2 million in 2022, then slumped by 73.95% to $12.0 million in 2023, then tumbled by 75.43% to $3.0 million in 2024, then soared by 111.3% to $6.2 million in 2025.
• Business Quant data shows DTIL's Current Deferred Revenue at $6.2 million in Q3 2025, $6.0 million in Q2 2025, and $5.7 million in Q1 2025.